Progressive Processing of Continuous Range Queries in Hierarchical Wireless Sensor Networks

In this paper, we study the problem of processing continuous range queries in a hierarchical wireless sensor network. Contrasted with the traditional approach of building networks in a "flat" structure using sensor devices of the same capability, the hierarchical approach deploys devices of higher capability in a higher tier, i.e., a tier closer to the server. While query processing in flat sensor networks has been widely studied, the study on query processing in hierarchical sensor networks has been inadequate. In wireless sensor networks, the main costs that should be considered are the energy for sending data and the storage for storing queries. There is a trade-off between these two costs. Based on this, we first propose a progressive processing method that effectively processes a large number of continuous range queries in hierarchical sensor networks. The proposed method uses the query merging technique proposed by Xiang et al. as the basis and additionally considers the trade-off between the two costs. More specifically, it works toward reducing the storage cost at lower-tier nodes by merging more queries, and toward reducing the energy cost at higher-tier nodes by merging fewer queries (thereby reducing "false alarms"). We then present how to build a hierarchical sensor network that is optimal with respect to the weighted sum of the two costs. It allows for a cost-based systematic control of the trade-off based on the relative importance between the storage and energy in a given network environment and application. Experimental results show that the proposed method achieves a near-optimal control between the storage and energy and reduces the cost by 0.989~84.995 times compared with the cost achieved using the flat (i.e., non-hierarchical) setup as in the work by Xiang et al.Comment: 41 pages, 20 figure

Two distinct red giant branch populations in the globular cluster NGC 2419 as tracers of a merger event in the Milky Way

Recent spectroscopic observations of the outer halo globular cluster (GC) NGC 2419 show that it is unique among GCs, in terms of chemical abundance patterns, and some suggest that it was originated in the nucleus of a dwarf galaxy. Here we show, from the Subaru narrow-band photometry employing a calcium filter, that the red giant-branch (RGB) of this GC is split into two distinct subpopulations. Comparison with spectroscopy has confirmed that the redder RGB stars in the $hk$[=(Ca$-b)-(b-y)$] index are enhanced in [Ca/H] by $\sim$0.2 dex compared to the bluer RGB stars. Our population model further indicates that the calcium-rich second generation stars are also enhanced in helium abundance by a large amount ($\Delta$Y = 0.19). Our photometry, together with the results for other massive GCs (e.g., $\omega$ Cen, M22, and NGC 1851), suggests that the discrete distribution of RGB stars in the $hk$ index might be a universal characteristic of this growing group of peculiar GCs. The planned narrow-band calcium photometry for the Local Group dwarf galaxies would help to establish an empirical connection between these GCs and the primordial building blocks in the hierarchical merging paradigm of galaxy formation.Comment: 4 pages, 4 figures, 1 table, accepted for the publication in ApJ

Monitoring daily evapotranspiration in Northeast Asia using MODIS and a regional Land Data Assimilation System

We applied an approach for daily estimation and monitoring of evapotranspiration (ET) over the Northeast Asia monsoon region using satellite remote sensing observations from the Moderate Resolution Imaging Spectroradiometer (MODIS). Frequent cloud cover results in a substantial loss of remote sensing information, limiting the capability of continuous ET monitoring for the monsoon region. Accordingly, we applied and evaluated a stand-alone MODIS ET algorithm for representative regional ecosystem types and an alternative algorithm to facilitate continuous regional ET estimates using surface meteorological inputs from the Korea Land Data Assimilation System (KLDAS) in addition to MODIS land products. The resulting ET calculations showed generally favorable agreement (root-mean-square error  \u3c 1.3 mm d−1) with respect to in situ measurements from eight regional flux tower sites. The estimated mean annual ET for 3 years (2006 to 2008) was approximately 362.0 ± 161.5 mm yr−1 over the Northeast Asia domain. In general, the MODIS and KLDAS-based ET (MODIS-KLDAS ET) results showed favorable performance when compared to tower observations, though the results were overestimated for a forest site by approximately 39.5% and underestimated for a cropland site in South Korea by 0.8%. The MODIS-KLDAS ET data were generally underestimated relative to the MODIS (MOD16) operational global terrestrial ET product for various biome types, excluding cropland; however, MODIS-KLDAS ET showed better agreement than MOD16 ET for forest and cropland sites in South Korea. Our results indicate that MODIS ET estimates are feasible but are limited by satellite optical-infrared remote sensing constraints over cloudy regions, whereas alternative ET estimates using continuous meteorological inputs from operational regional climate systems (e.g., KLDAS) provide accurate ET results and continuous monitoring capability under all-sky conditions

Multiplex polymerase chain reaction test for the diagnosis of acute viral hepatitis A

Background/AimsThe early diagnosis of acute hepatitis A (AHA) is hindered because serum IgM against hepatitis A virus (HAV) can yield false-negative results during the window period. This study evaluated the diagnostic accuracy of a polymerase chain reaction (PCR) kit for HAV RNA for the diagnosis of AHA.MethodsSamples were collected from 136 patients with acute severe hepatitis at their admission to Asan Medical Center between June 2010 and July 2010. Samples were analyzed for serum IgM anti-HAV using an immunoassay test and for qualitative HAV RNA using the Magicplex HepaTrio PCR test kit. The diagnostic accuracies of these methods were tested on the basis of clinical and laboratory diagnoses of AHA.ResultsThe concordance rate and kappa value between IgM anti-HAV and HAV RNA PCR were 88.2% and 0.707, respectively. For the diagnosis of AHA, the sensitivity and specificity of IgM anti-HAV were 90.7% and 100%, respectively, when an "equivocal" result was regarded as positive; and 79.1% and 100%, respectively, when an "equivocal" result was regarded as negative. The sensitivity and specificity of HAV RNA PCR were 81.4% and 100%, respectively. All four patients with negative IgM anti-HAV and positive HAV RNA PCR results and all four patients with equivocal IgM anti-HAV RNA and positive HAV RNA PCR results were eventually diagnosed with AHA.ConclusionsThe qualitative HAV RNA PCR test has an equivalent diagnostic accuracy for AHA compared to IgM anti-HAV and may be more sensitive during the window period

THE EFFECTS OF WHEELCHAIR CAMBER AND HANDRIM SIZE IN WHEELCHAIR BASKETBALL MOVEMENT

Improving the wheelchair design can be an important determinant of high performance in the wheelchair basketball. Researchers have focused on increasing the efficiency of the wheelchair, looking at the factors such as the seat position, handrim size, and wheel camber. Most handrim and wheel chamber studies, however, have focused only on the propulsive phase. Quick turn as well as fast propulsion is essential to the success in a wheelchair basketball game and the energy efficiency becomes particularly important in a prolonged wheelchair use. The purpose of this study was to investigate the effects of wheelchair camber and handrim size on the linear propulsion, turn velocity, and efficiency

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B

Antiviral therapy; IncidenceTerapia antiviral; IncidenciaTeràpia antiviral; IncidènciaBackground & Aims Antiviral therapy may attenuate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to explore how tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) affect HCC risk in patients with CHB. Methods The REACH-B, aMAP, and mPAGE-B models were utilized to assess HCC risk in patients with CHB from two global randomized-controlled trials evaluating the impact of TAF vs. TDF treatment. Standard incidence ratios (SIRs) were calculated using data from the REACH-B model as a ratio of observed HCC cases in the TAF- or TDF-treated patients vs. predicted HCC cases for untreated historical controls. Proportions of treated patients shifting aMAP and mPAGE-B risk categories between baseline and Week 240 were calculated. Results Of the 1,632 patients (TAF, n = 1,093; TDF, n = 539) followed for up to 300 weeks, 22 HCC cases developed. Those receiving TAF had an SIR that was lower compared to the SIR of individuals receiving TDF: 0.32 (p <0.001) vs. 0.56 (p = 0.06). In the general study population, individuals without cirrhosis at baseline had an SIR that was lower compared to the SIR of individuals with cirrhosis at baseline: 0.37 (p <0.001) vs. 0.58 (p = 0.15). Of the patients at low risk of HCC at baseline, the majority (97%) remained low risk by mPAGE-B and aMAP scoring at Week 240. Among those at medium or high risk at baseline, substantial portions shifted to a lower risk category by Week 240 (mPAGE-B: 22% and 42%; aMAP: 39% and 63%, respectively). Conclusions This evaluation provides evidence that treatment with TAF or TDF can reduce HCC risk in patients with CHB, particularly in patients without cirrhosis. Impact and implications Despite the substantial impact of HCC on long-term outcomes of patients with CHB, the differential risk of HCC development among those receiving treatment with TAF vs. TDF has not been well elucidated. Using three validated risk prediction models, we found that TAF is at least as effective as TDF in reducing HCC risk in patients with CHB. While TDF is well-studied in the context of HCC risk reduction, our novel findings underscore the effectiveness of TAF as a treatment option for patients with CHB. Clinical trial numbers NCT01940341; NCT02836249; NCT01940471; NCT02836236.This study was sponsored by Gilead Sciences. This article was based on the original studies GS-US-320-0108 and GS-US-320-0110 sponsored by Gilead Sciences. Support for third-party writing assistance for this article, provided by Julianna Catania, MPH, and Isabel Haber, BS, Costello Medical, US, was funded by Gilead in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3)